Back to list

BCG Strain Comparison

University of North Carolina at Chapel Hill


Description

This study will evaluate differences and effectiveness of two treatments on bladder cancer. Patients with newly diagnosed High Grade Non Muscle Invasive Bladder cancer who meet qualifications will be treated with standard BCG treatment or with Tokyo-172 BCG.


Keywords:

Cancer


Category:

Drug or Biologic

Qualifications

 


Age
18 - 99 years


Gender
Any


Study Population

Males and Females 18 and over with Bladder Cancer


Investigator

Matthew Nielsen
Associate Professor
Urology - Clinic

For questions, contact:

Chris Paterno
christoper_paterno@med.unc.edu
(919) 537-3505
Visit Website

Recruitment Period End

September 30, 2023

Location

Primary Location
UNC Urology Clinic
101 Manning Dr #2, Chapel Hill, NC 27514, USA

Study Qualifications

Gender Any

Age Range 18 - 99 years

Participant qualification(s) Must have confirmed high grade non muscle invasive bladder cancer, All visible bladder tumors removed within 30 days prior to registration in study

Not eligible if: Cannot have any renal or ureter cancer involvement. Cannot have had prior treatment with BCG

Number of Visits

    » 20 In person visit(s)

    1 Screening, 19 Clinic

    » 0 Remote visit(s)

Participation Period

60 months

Compensation

By clicking I am interested, your contact information will be sent to the researcher/study coordinator for this study. The coordinator will respond by email with additional information on how to proceed.